COMMUNIQUÉS West-GlobeNewswire

SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES
14/11/2025
Ghent Belgium, Nov. 14, 2025 (GLOBE NEWSWIRE) -- SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES PRESS RELEASE REGULATED INFORMATION 14 November 2025, 6 : 00 pm CET Ghent, Belgium, 14 [...]
Fagron completes share buy-back program
14/11/2025
Regulated information Nazareth (Belgium)/Rotterdam (The Netherlands), 14 November 2025 – 6PM CET Fagron completes share buy-back program In the period from 10 November 2025 through 14 November 2025, Fagron purchased 44, [...]
Positioning Barbados as the Caribbean’s Life Sciences Hub
14/11/2025
EarlyHealth City to Anchor US$200 Million Investment BRIDGETOWN, Barbados, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Export Barbados (BIDC) and EarlyHealth Group (EHG), headquartered in Dubai, United Arab Emirates, have signed [...]
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
14/11/2025
WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN ), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, [...]
CROSSJECT completes €5 million financing with Vatel Capital
14/11/2025
Press release CROSSJECT completes €5 million financing with Vatel Capital DIJON, France – November 14th, 2025 (8.30 PM CET) – CROSSJECT (ISIN: FR0011716265; Euronext: ALCJ), a specialty pharmaceuticals company that [...]
CROSSJECT lève 5 millions d'euros auprès de Vatel Capital
14/11/2025
Communiqué de presse CROSSJECT lève 5 millions d'euros auprès de Vatel Capital DIJON, France – 14 novembre 2025 (20H30 CET) – CROSSJECT (ISIN : FR0011716265 ; Euronext : ALCJ), société pharmaceutique de spécialités qui [...]
FDA Approves New Safety Warning and Revised Indication that Limits Use for Elevidys Following Reports of Fatal Liver Injury
14/11/2025
Silver Spring, Md., Nov. 14, 2025 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration today announced it is taking action to approve new labeling submitted by the company that includes the addition of a Boxed [...]
Biotricity Strengthens Path to Scalable Profitability with Sustained Margins & Operational Efficiency in Second Quarter Fiscal 2026
14/11/2025
REDWOOD CITY, CA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biotricity Inc. (OTCQB:BTCY) ("Biotricity" or the "Company”), an innovative Technology-as-a-Service (TaaS) company committed to redefining the landscape of the [...]
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $86.25 Million
14/11/2025
BRISBANE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a biopharmaceutical company advancing a late-stage clinical platform targeting neuroinflammation across life-changing [...]
Inhibikase Therapeutics Announces Third Quarter 2025 Financial Results and Highlights Recent Activity
14/11/2025
BOSTON and ATLANTA, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of [...]
Femasys Announces Third Quarter Financial Results for 2025
14/11/2025
– FDA Approval to Advance Final FemBloc ® Trial with Clear Pathway to Potentially Achieve U.S. FDA Approval – – $12 Million Financing Strengthens Balance Sheet and Extends Cash Runway – ATLANTA, Nov. 14, 2025 (GLOBE [...]
TOMI Environmental Solutions, Inc. Reports Q3 2025 Financial Results and Outlines Growth Initiatives
14/11/2025
FREDERICK, Md., Nov. 14, 2025 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. (NASDAQ: TOMZ), a global provider of disinfection and decontamination essentials through its premier Binary Ionization Technology® ( [...]
Terns Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
14/11/2025
FOSTER CITY, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that members of senior management will be [...]
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
14/11/2025
– Company reports $14.3 million in revenue in Q3’25, consisting of $3.6 million in YCANTH ® revenue and $10.7 million of license and collaboration revenue – – Reports positive feedback from the FDA and alignment [...]
Biogen Completes Acquisition of Alcyone Therapeutics
14/11/2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CNS therapy delivery [...]
CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
14/11/2025
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or “the Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting [...]
4DMT Announces New Employment Inducement Grants
14/11/2025
EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with [...]
Entera Bio Announces Third Quarter 2025 Financial Results and Business Updates
14/11/2025
FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study EB613 Phase 2 Data Demonstrating Consistent Efficacy across Younger Post-Menopausal Women with Osteoporosis and its Impact on Trabecular [...]
Health Catalyst to Participate in Upcoming Investor Conferences
14/11/2025
SALT LAKE CITY, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, today announced [...]

Pages